Skip to main content
. Author manuscript; available in PMC: 2013 May 22.
Published in final edited form as: Pediatr Blood Cancer. 2009 May;52(5):621–625. doi: 10.1002/pbc.21838

Figure 3.

Figure 3

Effect of hepatic dysfunction on cyclosporine exposure for Patient 2. Pop PK modeling with MW/PHARM (MediWare, Groningen, the Netherlands). As shown by the data, the half-life of the drug increased from approximately 5 hours to 42 hours.

HHS Vulnerability Disclosure